TransMedics (TMDX) Cash from Financing Activities (2018 - 2026)

TransMedics has reported Cash from Financing Activities for 9 years, with the latest figure at $970000.0 in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 86.32% year-over-year to $970000.0 in Q2 2026; TTM through Jun 2026 was $11.5 million, a 40.14% decrease from a year earlier, with the FY2025 full-year figure at $16.9 million, down 26.3% from the prior year.
• Cash from Financing Activities was $970000.0 for Q2 2026 at TransMedics, down from $3.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $394.0 million in Q2 2023, with the low at $237000.0 in Q2 2022.
• Average Cash from Financing Activities over 5 years is $34.0 million, with a median of $3.1 million recorded in 2024.
• The largest YoY upside for Cash from Financing Activities was 166150.21% in 2023 against a maximum downside of 99.07% in 2023.
• Over 5 years, Cash from Financing Activities stood at $3.1 million in 2022, then tumbled by 69.85% to $924000.0 in 2023, then gained by 28.35% to $1.2 million in 2024, then jumped by 161.3% to $3.1 million in 2025, then tumbled by 68.7% to $970000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $970000.0 (Q2 2026), $3.8 million (Q1 2026), and $3.1 million (Q4 2025), per Business Quant data.